Immunic
New York, New York, United States · Biotechnology
Immunic, Inc. is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company focuses on building a leading multiple sclerosis organization as it prepares for potential regulatory filings and commercialization efforts.
Key facts
- Headquarters
- New York, New York, United States
- Employees
- Unknown
- Industries
- Biotechnology
- Status
- Public (IMUX)
- Website
- immunic.com
Recent activity at Immunic
- : Immunic, Inc. Appoints Jaa Roberson as Chief People Officer
- : SEC 8-K (3.01): On January 5, 2026, Immunic, Inc. received approval from the Nasdaq Listing Qualifications Department to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. This transfer is set to take effect at the opening of business on January 7, 2026, under the trading symbol 'IMUX'. The Nasdaq Capital Market requires companies to meet certain financial and corporate governance standards, reflecting a strategic adjustment in the company's market positioning.
Leadership
- Jaa Roberson, Chief People Officer
- Jaa Roberson, Chief People Officer
Verified email and direct lines for Immunic’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Immunic in the news
- Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026 - PR Newswire (Oct 29, 2026)
- Immunic adds new Chief People Officer ahead of Phase 3 readout - Yahoo Finance (Oct 19, 2026)
- Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting - Investing News Network (Oct 21, 2026)
- Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting - PR Newswire (Oct 07, 2026)
- Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PR Newswire (Sep 09, 2026)
- Immune cell identifier and classifier (ImmunIC) for single cell transcriptomic readouts - Nature (Jul 26, 2023)
- Ukraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back? - Pharma Voice (Apr 16, 2024)
- Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - PR Newswire (Sep 01, 2026)
Companies similar to Immunic
- Scarlet · Biotechnology
- Cambium · Biotechnology
- Replimune · Biotechnology
- Capitan Orthopedics · Biotechnology
- Stride · Biotechnology
About Immunic: questions and answers
What does Immunic do?
Immunic, Inc. is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company focuses on building a leading multiple sclerosis organization as it prepares for potential regulatory filings and commercialization efforts.
Where is Immunic headquartered?
Immunic is headquartered in New York, New York, United States.
What is the latest news on Immunic?
On Oct 19, 2026, Immunic, Inc. Appoints Jaa Roberson as Chief People Officer
Is Immunic a public company?
Yes. Immunic is publicly traded under the ticker IMUX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy